A Strategy to Design Protein-based Antagonists Against Type I Cytokine Receptorsdoi:10.26249/FK2/NPX7DUosnaData2024-08-301Pollmann, Christoph, 2024, "A Strategy to Design Protein-based Antagonists Against Type I Cytokine Receptors", https://doi.org/10.26249/FK2/NPX7DU, osnaData, V1A Strategy to Design Protein-based Antagonists Against Type I Cytokine Receptorsdoi:10.26249/FK2/NPX7DUPollmann, ChristophosnaDataPollmann, ChristophPollmann, Christoph2024-08-30Medicine, Health and Life SciencesExcessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune or hematopoietic disorders. Here we leverage protein design to create tailored cytokine receptor blockers with idealized properties. Specifically, we aimed to tackle the granulocyte-colony stimulating factor receptor (G-CSFR), a mediator of different types of leukemia and autoinflammatory diseases. By modifying designed G-CSFR binders, we engineered hyper-stable proteins that function as nanomolar signaling antagonists. X-ray crystallography showed atomic-level agreement with the experimental structure of an exemplary design. Furthermore, the most potent design blocks G-CSFR in acute myeloid leukemia cells and primary hematopoietic stem cells. Thus, the resulting designs can be used for inhibiting or homing to G-CSFR-expressing cells. Our work also demonstrates that designed cytokine mimics can be used to derive non-activating variants for tackling a range of cytokine receptors.CC0 WaiverLink to raw data: https://omero.cellnanos.uni-osnabrueck.de/webclient/?show=project-15707